Skip to main content

Table 3 Secondary efficacy outcomes, Uganda therapeutic efficacy monitoring 2018–2019

From: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda

Secondary Efficacy outcome Kwania district Arua district Busia district
AL DP AL DP AL DP
Parasitemia prevalence n (%)
 Day 1 72 (69.2) 65 (68.4) 98 (99.0) 88 (91.7) 93 (91.2) 75 (79.8)
 Day 2 14 (13.5) 11 (11.6) 46 (46.5) 31 (32.3) 9 (8.8) 7 (7.5)
 Day 3 0 (0.0) 1 (1.1) 3 (3.0) 2 (2.1) 0 (0.0) 0 (0.0)
Fever prevalence n (%)
 Day 1 2 (1.96) 4 (4.2) 6 (6.13) 9 (9.3) 5 (4.9) 2 (2.1)
 Day 2 0 (0.0) 1 (1.1) 0 (0.0) 1 (1.0) 4 (3.9) 0 (0.0)
 Day 3 0 (0.0) 1 (1.1) 0 (0.0) 0 (0.0) 2 (2.0) 0 (0.0)
Gametocyte prevalence n (%)
 Day 1 1 (1.0) 1 (1.1) 4 (4.0) 6 (6.3) 11 (10.8) 15 (16.0)
 Day 2 0 (0.0) 1 (1.1) 4 (4.0) 6 (6.3) 5 (4.9) 13 (13.8)
 Day 3 0 (0.0) 0 (0.0) 3 (3.0) 6 (6.3) 3 (2.9) 12 (12.8)
 Day 4–28 (AL) or 42 (DP) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.0) 0 (0.0) 1 (0.1)
  1. AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine